Le Lézard
Classified in: Health
Subjects: PER, ACC

The board member Philipp von Hugo resigns from Immunovia's board at his own request


LUND, Sweden, May 6, 2023 /PRNewswire/ -- Philipp von Hugo, member of the board of directors of Immunovia AB (publ) ("Immunovia" or the "Company"), has at his own request notified his resignation from the Board of Directors of the Company and therefore declines re-election at annual general meeting on 26 May 2023.

Philipp von Hugo, who has served as board member of Immunovia since the annual general meeting in 2022, has on 5 May 2023 at his own request with immediate effect, notified his resignation from his position as board member of Immunovia and consequently declines re-election, at the annual general meeting on 26 May 2023.

The Nomination Committee of the Company has been informed of his decision.

"We thank Philipp for his commitment to the board and wish him the best in his future engagements", comments the chair of the Board of Directors Carl Borrebaeck.

FOR MORE INFORMATION, PLEASE CONTACT:

Carl Borrebaeck
Chair of the Board of Directors
[email protected]
+46 70 821 83 30

Karin Almqvist Liwendahl
Chief Financial Officer
[email protected]
+46 709 11 56 08

ABOUT IMMUNOVIA

Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. The company is headquartered in Lund, Sweden. Immunovia's shares are listed on Nasdaq Stockholm. For more information please visit www.immunovia.com.

The following files are available for download:

https://mb.cision.com/Main/13121/3765124/2038906.pdf

Press release (PDF)

SOURCE Immunovia AB


These press releases may also interest you

at 04:45
ERS Genomics Limited (?ERS'), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS' CRISPR/Cas9 patent portfolio....

at 03:15
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....



News published on and distributed by: